References
XTEND-ed is ongoing. Data cut: 22 February 2024. *For minor and moderate bleeding episodes occurring within 2–3 days after a prophylactic dose, a lower dose of 30 IU/kg dose may be used. Additional doses of 30 or 50 IU/kg every 2–3 days may be considered. For major bleeding, additional doses of 30 or 50 IU/kg every 2–3 days can be considered;1
†For minor surgery, an additional dose of 30 or 50 IU/kg after 2–3 days may be considered. For major surgery, additional doses of 30 or 50 IU/kg every 2–3 days may be administered as clinically needed for perioperative management;1
‡Assessment of response to ALTUVOCT treatment of individual bleeding episodes based on the ISTH 4-point response scale; §Investigators' or Surgeons' assessment of participant’s haemostatic response to ALTUVOCT treatment on the ISTH 4-point response for surgical procedures scale. AE, adverse event; ISTH, International Society on Thrombosis and Haemostasis; PwHA, people living with haemophilia A; TEAE, treatment emergent adverse event.
- Sobi. ALTUVOCT SmPC, 2026
- Klamroth R et al. Haemophilia 2025;0:1–10;
- Chan A et al. EAHAD 2025. Milan, Italy, 4–7 February 2025. ABS1243;
- Chowdary P, et al. ISTH 2025. Washington DC. USA, 21–25 June 2025. PB0847